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A B S T R A C T
Background: The Vibrant Soundbridge middle ear implant and the Bonebridge bone conducting hearing device
are hearing implants that use radio frequency transmission to send information from the sound processor to the
internal transducer. This reduces the risk of skin problems and infection but requires a more involved surgical
procedure than competitor skin penetrating devices. It is not known whether more complex surgery will lead to
additional complications. There is little information available on the reliability of these systems and adverse
medical or surgical events. The primary research question is to determine the reliability and complication rate
for the Vibrant Soundbridge and Bonebridge. The secondary research question explores changes in quality of life
following implantation of the devices. The tertiary research question looks at eﬀectiveness via changes in au-
ditory performance.
Method: The study was designed based on a combination of a literature search, two clinician focus groups and
expert review.
A multi-centre longitudinal observational study was designed. There are three study groups, two will have
been implanted prior to the start of the study and one group, the prospective group, will be implanted after
initiation of the study. Outcomes are surgical questionnaires, measures of quality of life, user satisfaction and
speech perception tests in quiet and in noise.
Conclusion: This is the ﬁrst multi-centre study to look at these interventions and includes follow up over time to
understand eﬀectiveness, reliability, quality of life and complications.
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1. Introduction
Implantable hearing devices that directly stimulate middle ear
structures (middle ear implants; MEI) or provide direct bone conduc-
tion to transmit sound to the inner ear (bone conducting hearing de-
vices; BCHD) are becoming routinely used within the United Kingdom
National Health Services (NHS). These devices are used by hearing
impaired individuals who cannot use conventional acoustic hearing
aids.
A traditional BCHD has two parts: an external sound processor and a
surgically implanted connector ﬁxed in the bone behind the ear. The
connector projects through the skin and attaches to the processor which
contains a microphone and hearing aid circuitry producing vibration to
the skull and in turn the cochlea bypassing the outer and middle ear.
In the last two decades, there has been an increase in the use of
devices where the implantable component which is activated via radio
frequency from an external sound processor rather than by a mechan-
ical link directly through the skin. Such devices have been produced by
MED-EL (www.medel.com). The MED-EL devices are a MEI the Vibrant
Soundbridge (VSB; CE Mark 1997 & FDA approval 2000) and a BCHD
the Bonebridge (BB; CE Mark 2012 & FDA approval in process).
In the VSB and BB sound is picked up by the microphone of the
external sound processor held over the receiver of the internal com-
ponent by magnetism without skin penetration. The processor transmits
electrical signals through the skin activating the moving components of
the device, either driving a middle ear structure (VSB) or producing
vibrations in the skull (BB), transmitting to the cochlea via bone con-
duction.
Without physical connection through a permanent opening in the
skin, these devices potentially reduce opportunity for traumatic, in-
fective or other medical complications. However, the implantation is
more complex than for implantable percutaneous BCHDs, which may in
turn lead to other opportunities for surgical complications.
A systematic review was conducted [17] of the impact on hearing of
MEIs compared with conventional hearing aids. They concluded that
some patients gain beneﬁt from MEIs, but high-quality, long-term stu-
dies were not available, providing motivation for this research.
Comparison data are available for other BCHDs. It was reported that
4.5% of one clinics 602 BCHD caseload required device removal [16];
2% due to pain, 1.2% due to infection, and the remaining due to a
variety of other reasons. To conduct a comparative review of outcome
with suﬃcient cases for the VSB and BB a multi-site study is required to
overcome the relatively small number of implantations at individual
sites.
This research is important for clinicians and commissioners devel-
oping services, patients considering treatment and the National
Institute of Health and Care Excellence (NICE) who develop NHS
guidelines for the UK. NICE produced guidelines on Auditory Brainstem
Implants in 2005 [12], Cochlear Implants in 2009 [13] and have re-
leased guidance on Hearing Loss (adult presentation) in 2017. Ulti-
mately, they may produce guidelines for all implantable auditory de-
vices and will require high quality data to be able to develop evidence-
based guidance.
The primary research question for this trial looks at the reliability
and medical complication rate of the VSB and BB, the secondary re-
search question explores changes in quality of life and the tertiary re-
search question looks at the change in auditory performance.
2. Methods
The study design was developed through two focus group meetings
involving representatives from eleven auditory implant centres in the
UK, together with representatives from MED-EL and the chief in-
vestigators from University College London (UCL). The discussions
were facilitated by the chief investigators from UCL.
Prior to the ﬁrst focus group a draft study protocol was developed
based upon a literature search to identify the most important outcomes
used in the ﬁeld. These outcomes fell under the following themes:
medical complications, functional outcomes and quality of life. These
themes were then used to inform the research questions. In the ﬁrst
focus group the themes were discussed with respect to how the data
could be collected as part of clinical routine. The amended protocol was
then prepared and the second focus group was conducted to reﬁne the
details.
The focus groups discussed the patient pathways, relevant audio-
logical practice, functional outcome measures and the recording of
medical procedures and complications used routinely in clinical prac-
tice. Through a process of discussion and consensus the assessment,
ﬁtting and patient management protocols were developed. All study
sites agreed to follow the same protocols to enable quality data col-
lation.
To be able to collect the information on the surgical and medical
complications a questionnaire was developed for each implant (VSB
and BB) because the tools were not available for this purpose. The
development of this is explained in Saeed et al. [15].
2.1. Ethics approval
Multi-site NHS ethical approval (15YH 0229) with National Institute
Health Research (NIHR) portfolio adoption and site speciﬁc information
(SSI) approvals are in place at the participating study sites.
2.2. Study design
The developed study design is a multi-centre longitudinal observa-
tional study.
There are three main data collection groups:
1) Prospective participants (assessed and implanted following study
initiation)
2) Retrospective follow up participants (assessed and implanted prior
to study initiation but enlisted for follow up assessments according
to study protocols)
3) Retrospective participants (existing patient data obtained via notes
review)
The former two groups involve the attendance by the patients at
clinic to undergo the perceptual assessment test battery.
The analysis will look at rate of device survival and medical com-
plication over time, as well as changes in auditory performance and
quality of life.
It was decided that assessments will be conducted at standard ap-
pointment times and all audiological tests and patient questionnaires
would be standardized and in addition, wherever possible ques-
tionnaires would be self-administered.
2.3. Data collection
It was concluded that audiological measures and the speech tests
will be administered by the audiologists or speech and language
therapists who will also complete the case report forms for the study.
The surgical questionnaires will be completed either by the surgeon or
audiologist based on the notes. Quality of life and device satisfaction
questionnaires will be self-completed by the patients.
2.4. Demographic information
The following demographic information will be the minimum data
set for the study to be able to account for any confounds in the analysis.
When the data for each individual are reported on the Case Report Form
a code will be used to pseudo-anonymise the data collection:
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• Gender
• Age at implantation
• Onset of hearing loss (calculated from when they thought their
hearing loss was at the level they experienced prior to implantation)
• Home language and which is the ﬁrst language for the individual
• Aetiology of Deafness
• Additional Diﬃculties
• Any other factors that may aﬀect outcomes
• Device in left ear (make and model)
• Device in right ear (make and model)
• Listening conﬁguration during testing (e.g. individuals may use a
hearing aid or cochlear implant in the other ear)
2.5. Participant numbers
The power analysis was conducted for the prospective group only.
The primary outcome for this arm of the study was the Health Utilities
Index questionnaire (HUI23) which is a combination of two versions,
which is a validated stand-alone questionnaire [6]. The power calcu-
lation indicated that there should be 24 participants in each group
based on a medium eﬀect size (0.57). Therefore in total across the ten
study sites there should be 72 participants in total because there are
three sub-groups for analysis, these are: Soundbridge for individuals
with conductive or mixed losses, Soundbridge for individuals with
sensori-neural losses and Bonebridge for conductive losses.
For the two retrospective groups all data that is available will be
collated.
2.6. Audiology and speech measures
A standard pure-tone audiogram will be recorded pre-implanta-
tion for octave frequencies from 250 to 8000 Hz and bone-conduction
thresholds will be measured from 500 to 4000 Hz.
A soundﬁeld audiogram using either warble tones or narrow-band
noises will be conducted to determine the thresholds across the fre-
quency range (from 250 to 4000 Hz in octave steps) post-implantation
and in aided conditions pre- and post-implantation.
Sentence perception in quiet will be assessed with the Bamford
Kowal Bench (BKB [1]; sentence test presented at 50 dBA and 40 dBA,
spoken by a male talker, presented from a speaker 1m in front of the
listener. The minimum dataset will be to only present the stimuli at 40
dBA. The percent key words understood correctly in the sentence will
be recorded.
In addition sentence perception in noise will be conducted using
BKB sentences. This would either be with ﬁxed level noise presentation
with the noise presented at a level to avoid ceiling and ﬂoor eﬀects or
alternatively with an adaptive version of the BKB sentence test in noise
in which the test adjusts the signal-to-noise ratio to determine the level
where 50% of speech is perceived. The minimum test conﬁguration is
for speech and noise to be presented from the same speaker 1m in front
of the listener.
To assess spatial speech perception with bilateral hearing impair-
ment, there will be three conditions, the ﬁrst condition will involve
speech and noise being presented from the same speaker, the second
condition will involve the speech being presented from the speaker in
front and the noise will be presented from a speaker at 90° on the left.
The third condition will involve the noise being presented from 90° on
the right. The diﬀerence between scores with speech and noise pre-
sented from the same speaker minus the scores for each side at 90° is the
spatial release from masking.
In the cases of single-sided deafness the conﬁguration will be that
speech is presented through a speaker on one side and the noise on the
opposite side and repeated in the reverse conﬁguration to determine the
beneﬁt obtained for speech in noise from the hearing device.
Word perception in quiet will be assessed with the Arthur
Boothroyd (AB [3]; monosyllabic word test (one syllable real words).
The test comprises of 13 lists of 10 words of which three lists will be
presented in each condition (i.e. 30 words). Each word list is equiva-
lent, eight of the words in each group assess consonant contrasts and
two assess vowel contrasts. A recording of a spoken word is presented
and the participant repeats what they hear. Stimuli will be produced by
a male talker, from a loudspeaker 1m in front of the listener at 50 dBA
and 40 dBA with the minimum dataset being 30 words presented at 50
dBA.
The self-completion of the Health Utilities Questionnaire (HUI23)
will be used. It is a standardized multi-attribute questionnaire looking
at health status and provides a single summary score of the health-re-
lated quality of life. This questionnaire can only be used with the
prospective group because it speciﬁcally relates to health status in the
last four weeks.
The retrospective assessment group will use the validated Glasgow
Beneﬁt Inventory (GBI [14]; which is a patient-reported questionnaire
evaluating the change in quality of life following an intervention. For
this questionnaire the comparison is made between before and after
receiving the intervention so the time aspect is not as critical as for the
HUI23.
In addition, to evaluate spatial hearing, centres can use the Speech,
Spatial, Qualities Questionnaire [8]. This is a standardized ques-
tionnaire which is used to assess spatial speech perception in the real-
world.
Finally, the Hearing Device Satisfaction Scale will be used to
capture any device speciﬁc information relating to usage and satisfac-
tion. This questionnaire was developed by the implant company
Symphonix.
2.7. Participant inclusion criteria
2.7.1. Prospective data collection
Newly implanted adults and children over the age of 5 years using a
VSB or BB from the date at which the hospital obtained Site Speciﬁc
Information approval. Each participant will be consented and followed
for a minimum of 6 months and data from all participants will be re-
corded until July 31st, 2018. There will be three main demographic
groups based on conﬁguration of hearing loss type and device. These
are: 1) VSB users with conductive or mixed hearing losses (both con-
ductive and sensorineural), 2) VSB used with sensori-neural losses & 3)
BB with conductive or mixed hearing impairments.
2.7.2. Retrospective follow up
Adults and children implanted with a VSB or BB prior to the start of
the study who still attend clinic for follow up appointments will be
recruited into this group. All retrospective data will be collated and the
surgical questionnaires completed. At the point where the patient visits
the clinic for a routine clinical appointment they would be consented
for the study and the standard assessment test battery would be con-
ducted, including questionnaires but the HUI would be replaced with a
GBI.
2.7.3. Retrospective data collection
Adults and children implanted with a VSB or BB prior to the start of
the study who no longer visit clinic for follow-up would be recruited
into this group. Surgical questionnaires and a record of any assessment
scores will be recorded.
2.8. Data collection points
2.8.1. Prospective group
There will be a minimum of 6 months data collection for each in-
dividual. Data will be collected at the following time points as a
minimum data set:
Pre-implant where assessments and self-completion questionnaires
will be completed.
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Surgery in which the intra-operative surgical questionnaire will be
completed.
Initial ﬁtting where patient speciﬁc set up, adjustment of device,
results of performance assessments and self-completion questionnaires
will be recorded.
1–3 months post-ﬁtting where assessments and self-completion
questionnaires completed.
6–9 months post-ﬁtting where assessments and self-completion
questionnaires completed.
The assessments and questionnaires will be completed at each
follow-up appointment afterwards until study close.
At the initial ﬁtting and the appointments afterwards the surgical
questionnaire will be updated to capture any medical/surgical/device
issues that happen over time.
2.9. Retrospective follow up group
For this group at the point when they attend clinic the assessments
and self-completion questionnaires will be completed and the surgical
questionnaires will be ﬁlled in to capture any details of problems that
occurred over the entire time period that the individual had their de-
vice. Over this time period any results of audiological or speech per-
ception tests will also be recorded.
2.10. Retrospective group
There will be no assessment points for this group. Patient notes will
be reviewed and the surgical questionnaire completed relating to the
entire time period that the individuals have their. In addition any
audiological and speech perception results will be recorded.
3. Discussion and conclusion
The ﬁnal protocol will be followed by all study sites producing the
ﬁrst multi-centre evaluation of surgical and performance outcomes in
VSB and BB users. These ﬁndings will be compared to similar studies for
other BCHDs to determine how the devices compare on reliability and
complications [10]; [5,9]. A survival analysis will be conducted based
on surgical questionnaires to map out potential complications that may
arise, the associated time course and frequency of occurrence. Other
measures to be compared to the literature will be patient satisfaction,
beneﬁt and quality of life [4,7,18], soundﬁeld hearing thresholds
[2,4,11] and speech perception [2,4,11]. Changes in surgical practice
that have occurred over time will be considered in the review to de-
termine the impact that these may have had on performance.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.
doi.org/10.1016/j.conctc.2018.03.007.
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